Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma: Case Report

Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma: Case Report

The spread of next-generation sequencing enables clinicians to identify rare oncogene alterations, including MET exon 14 skipping mutation, in clinical practice for NSCLC. Several tyrosine kinase inhibitors for MET exon 14 skipping mutation such as capmatinib and tepotinib have elucidated their effe...

Full description

Bibliographic Details
Main Authors: Taira Ninomaru, MD, Hideaki Okada, MD, Mika Fujishima, MD, PhD, Kei Irie, PhD, Shoji Fukushima, PhD, Akito Hata, MD
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:JTO Clinical and Research Reports
Subjects:
Tepotinib
MET exon 14 skipping mutation
Leptomeningeal metastases
Non–small cell lung cancer
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000047

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000047

Similar Items